OncoGenex to Webcast Third Quarter Financial Results on Thursday, November 4,
2010

BOTHELL, WA and VANCOUVER, Oct. 21 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter financial results will be released on Thursday, November 4, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's third quarter results and provide an update on the business, the recent financing and anticipated use of proceeds to advance the product pipeline.

To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing [phone] (U.S. & Canada) or [phone] (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. 

More information about OncoGenex is available at www.oncogenex.com.

For further information: